Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||LMP/BARF1/EBNA1-specific cytotoxic T lymphocytes|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|LMP/BARF1/EBNA1-specific cytotoxic T lymphocytes||LMP/BARF1/EBNA1-specific CTLs|LMP1/BARF1/EBNA-1 MABEL CTLs||LMP/BARF1/EBNA1-specific cytotoxic T lymphocytes are T-cells that recognize the Epstein-Barr virus proteins LMP, BARF1, and EBNA1, potentially resulting in increased anti-tumor immune response against cells expressing these proteins (NCI Drug Dictionary).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT02287311||Phase I||LMP/BARF1/EBNA1-specific cytotoxic T lymphocytes Cyclophosphamide + Fludarabine||Most Closely Matched 3rd Party Rapidly Generated LMP, BARF1 And EBNA1 Specific CTL, EBV-Positive Lymphoma (MABEL)||Recruiting||USA||0|